Michael Zinda Ph.D.
Net Worth

Last updated:

What is Michael Zinda Ph.D. net worth?

The estimated net worth of Dr. Michael Zinda Ph.D. is at least $4,218,765 as of 1 Apr 2024. He owns shares worth $109,300 as insider, has earned $1,180,215 from insider trading and has received compensation worth at least $2,929,250 in Repare Therapeutics Inc..

What is the salary of Michael Zinda Ph.D.?

Dr. Michael Zinda Ph.D. salary is $585,850 per year as Executive Vice President & Chief Scientific Officer in Repare Therapeutics Inc..

How old is Michael Zinda Ph.D.?

Dr. Michael Zinda Ph.D. is 54 years old, born in 1971.

What stocks does Michael Zinda Ph.D. currently own?

As insider, Dr. Michael Zinda Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Repare Therapeutics Inc. (RPTX) Executive Vice President & Chief Scientific Officer 71,908 $1.52 $109,300

What does Repare Therapeutics Inc. do?

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

RPTX logo
RPTX
Repare Therapeutics Inc.
$1.52

Michael Zinda Ph.D. insider trading

Repare Therapeutics Inc.

Dr. Michael Zinda Ph.D. has made 20 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 410 units of RPTX stock worth $1,911 on 1 Apr 2024.

The largest trade he's ever made was exercising 115,000 units of RPTX stock on 18 Jan 2022. As of 1 Apr 2024 he still owns at least 71,908 units of RPTX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Shares 410 $4.66 $1,911
Sale
Common Shares 450 $4.64 $2,088
Sale
Common Shares 450 $4.62 $2,079
Sale
Common Shares 450 $4.61 $2,075
Sale
Common Shares 450 $4.78 $2,151
Sale
Common Shares 2,869 $12.02 $34,485
Sale
Common Shares 6,404 $12.03 $77,040
Sale
Common Shares 1,200 $12.04 $14,448
Sale
Common Shares 533 $11.3 $6,023
Option
Employee Stock Option (right to buy) 115,000 $15.63 $1,797,450
Option
Common Shares 46,041 $1.94 $89,320
Option
Employee Stock Option (right to buy) 41,919 $2.04 $85,557
Sale
Common Shares 20,000 $27.54 $550,700
Sale
Common Stock 15,000 $32.48 $487,215
Sale
Common Stock 15,000 N/A N/A
Sale
Common Stock 19,696 N/A N/A
Sale
Common Stock 15,048 N/A N/A
Option
Common Stock 48 N/A N/A
Option
Employee Stock Option (right to buy) 48 N/A N/A
Option
Common Stock 432 N/A N/A
Option
Employee Stock Option (right to buy) 432 N/A N/A
Sale
Common Stock 432 N/A N/A
Option
Common Stock 16,235 N/A N/A
Option
Employee Stock Option (right to buy) 16,235 N/A N/A
Sale
Common Stock 16,235 N/A N/A
Sale
Common Stock 41,312 N/A N/A
Option
Common Stock 41,312 N/A N/A
Option
Employee Stock Option (right to buy) 41,312 N/A N/A
Option
Employee Stock Option (right to buy) 40,000 N/A N/A
Option
Common Stock 40,000 N/A N/A
Sale
Common Stock 40,000 N/A N/A
Option
Common Stock 8,321 N/A N/A
Option
Employee Stock Option (right to buy) 8,321 N/A N/A
Sale
Common Stock 8,321 N/A N/A
Option
Common Stock 8,956 N/A N/A
Option
Common Stock 8,956 $1.64 $14,661
Sale
Common Stock 8,956 N/A N/A
Option
Employee Stock Option (right to buy) 8,956 N/A N/A
Option
Employee Stock Option (right to buy) 8,956 $1.64 $14,661

Repare Therapeutics key executives

Repare Therapeutics Inc. executives and other stock owners filed with the SEC: